Literature DB >> 24081891

[Consensus document on spasticity in patients with multiple sclerosis. Grupo de Enfermedades Desmielinizantes de la Sociedad Española de Neurología].

Celia Oreja-Guevara1, Xavier Montalban, Clara de Andrés, Bonaventura Casanova-Estruch, Delicias Muñoz-García, Inmaculada García, Óscar Fernández.   

Abstract

INTRODUCTION: Multiple sclerosis is a chronic neurological inflammatory demyelinating disease. Specialists involved in the symptomatic treatment of this disease tend to apply heterogeneous diagnostic and treatment criteria. AIM: To establish homogeneous criteria for treating spasticity based on available scientific knowledge, facilitating decision-making in regular clinical practice. DEVELOPMENT: A group of multiple sclerosis specialists from the Spanish Neurological Society demyelinating diseases working group met to review aspects related to spasticity in this disease and draw up the consensus. After an exhaustive bibliographic search and following a metaplan technique, a number of preliminary recommendations were established to incorporate into the document. Finally, each argument was classified depending on the degree of recommendation according to the SIGN (Scottish Intercollegiate Guidelines Network) system. The resulting text was submitted for review by the demyelinating disease group. An experts' consensus was reached regarding spasticity triggering factors, related symptoms, diagnostic criteria, assessment methods, quality of life and therapeutic management (drug and non-drug) criteria.
CONCLUSION: The recommendations included in this consensus can be a useful tool for improving the quality of life of multiple sclerosis patients, as they enable improved diagnosis and treatment of spasticity.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24081891

Source DB:  PubMed          Journal:  Rev Neurol        ISSN: 0210-0010            Impact factor:   0.870


  5 in total

Review 1.  Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex®): A Review in Multiple Sclerosis-Related Spasticity.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2017-04       Impact factor: 9.546

2.  Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study.

Authors:  Rainel Sánchez-de la Rosa; Laura García-Bujalance; José Meca-Lallana
Journal:  Health Econ Rev       Date:  2015-10-16

Review 3.  [Effectiveness of acupuncture in spasticity of the post-stroke patient. Systematic review].

Authors:  Juan Rodríguez-Mansilla; Luis Espejo-Antúnez; Ana Isabel Bustamante-López
Journal:  Aten Primaria       Date:  2015-07-10       Impact factor: 1.137

4.  A real-world evidence study of nabiximols in multiple sclerosis patients with resistant spasticity: Analysis in relation to the newly described 'spasticity-plus syndrome'.

Authors:  Francesco Patti; Clara Grazia Chisari; Óscar Fernández; Jorge Sarroca; Elena Ferrer-Picón; Francisco Hernández Vicente; Carlos Vila Silván
Journal:  Eur J Neurol       Date:  2022-06-07       Impact factor: 6.288

Review 5.  Spasticity in multiple sclerosis and role of glatiramer acetate treatment.

Authors:  Jose Eustasio Meca-Lallana; Rocío Hernández-Clares; Ester Carreón-Guarnizo
Journal:  Brain Behav       Date:  2015-07-14       Impact factor: 2.708

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.